Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Oct. 31, 2021
Oct. 31, 2020
Cash flow from operating activities:    
Net loss $ (77,175) $ (27,166)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 5,638 4,248
Bad debt expense 47 427
Stock-based compensation expense, net of amounts capitalized 37,953 32,713
Non-cash interest paid in kind and discount amortization 3,266 3,494
Deferred income taxes 1 130
Other noncash items, net (1,187) (149)
Changes in operating assets and liabilities:    
Accounts receivable 12,741 22,819
Prepaid expenses and other current assets (1,104) (1,837)
Other noncurrent assets (1,817) 5,182
Accounts payable (5,774) 586
Accrued expenses and other current liabilities 16,413 (335)
Deferred revenue (7,132) (24,235)
Other liabilities 197 (103)
Net cash (used in) provided by operating activities (17,933) 15,774
Cash flow from investing activities:    
Purchases of marketable securities (61,758) (170,035)
Sales of marketable securities 56,652 0
Maturities of marketable securities 197,555 0
Purchases of property and equipment (5,197) (2,078)
Capitalized internal-use software (4,150) (2,504)
Acquisitions, net of cash acquired (3,625) 0
Net cash provided by (used in) investing activities 179,477 (174,617)
Cash flow from financing activities:    
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions and other offering costs 275,974 0
Proceeds from issuance of convertible preferred stock, net of issuance costs 0 191,752
Proceeds from senior subordinated secured convertible notes 0 73,425
Proceeds from issuance of stock warrants 0 7,639
Proceeds from short-term borrowings 0 49,973
Repayments of short-term borrowings 0 (49,973)
Payments of debt and equity issuance costs 0 (160)
Proceeds from issuance of common stock upon exercise of stock options 17,891 13,375
Net cash provided by financing activities 293,865 286,031
Effect of exchange rate fluctuations on cash and cash equivalents (1,060) (251)
Net change in cash and cash equivalents 454,349 126,937
Cash and cash equivalents at beginning of period 68,037 10,470
Cash and cash equivalents at end of period 522,386 137,407
Supplemental disclosure of cash flow information    
Cash paid for income taxes 2,525 2,290
Cash paid for interest 0 319
Supplemental disclosure for noncash investing and financing    
Net exercise of common stock warrants 18 0
Stock-based compensation expense capitalized in internal-use software 465 0
Accrued purchases of property and equipment 126 182
Common stock issued in exchange for other noncash assets $ 0 $ 5,000